lentilactobacillus hilgardii subsp gravesensis atcc 27305 hmp id 496  (ATCC)

Journal: Antibiotics

Article Title: In Silico Identification and Molecular Characterization of Lentilactobacillus hilgardii Antimicrobial Peptides with Activity Against Carbapenem-Resistant Acinetobacter baumannii

doi: 10.3390/antibiotics14101004

Figure Lengend Snippet: Inhibition by size-fractionated Lentilactobacillus hilgardii supernatants. L. hilgardii ATCC 27305 conditioned media was fractionated using Amicon Ultra centrifugal filters with a molecular weight cut-off of 100 kDa, 30 kDa, 10 kDa, or 3 kDa. Filtered conditioned media was co-incubated with A. baumannii in liquid BHI media for 24h to test for inhibition of planktonic growth ( A ) or dispersal pre-form biofilms ( B ). L. hilgardii ATCC 27305-conditioned media was also boiled, at 95 °C for 10 and 30 min, and 100 °C for 10 min, and tested for inhibition of planktonic growth ( C ) and dispersal of pre-formed biofilms ( D ). MRS is the media control. Experiments were performed in triplicate with error bars representing standard deviations. Black dots are values of individual replicates. For the non-parametric Kruskal–Wallis tests, asterisks denote the level of significance observed: ns, not significant; * p ≤ 0.05, *** p ≤ 0.001, and **** p ≤ 0.0001.

Article Snippet: Protein-coding sequences (CDSs) from the genome of Lentilactobacillus hilgardii subsp. gravesensis ATCC 27305 HMP ID 496 (GenBank: NZ_GG669709 , Biosample: SAMN00001468) were searched for matches to a custom comprehensive and non-redundant antimicrobial peptide database using NCBI BLAST 2.11.0+ [ ].

Techniques: Inhibition, Molecular Weight, Incubation, Control

Journal: Molecular Therapy. Nucleic Acids

Article Title: RNA activation of CEBPA improves leukemia treatment

doi: 10.1016/j.omtn.2025.102611

Figure Lengend Snippet: MTL-CEBPA sensitizes MOLM-14 cells to the anti-proliferative effects of FLT3 inhibitors (A) Heatmap of FLT3 inhibitors showing IC 50 values when combined with MTL-CEBPA or control (MTL-FLUC) in MOLM-14-Ven-Luc cells. The fold change in the IC50 (control vs. MLT-CEBPA) for each FLT3 inhibitor is listed next to the heatmap. (B) Difference in gilteritinib IC 50 in MOLM-14-Ven-Luc cells treated with MTL-CEBPA or control (MTL-FLUC). Two-way unpaired student t test; n = 3. Data represented as mean (SD). (C) Growth curves for MOLM-14 cells following treatment with 10 μg/mL of MTL-CEBPA or control (MTL-FLUC) with and without 5 nM gilteritinib. Two-way ANOVA with Holm-Sidak multiple comparison test; n = 6. Data represented as mean (SEM). (D) Percent viability of cells on day 6. Two-way unpaired student t test; n = 6. Data represented as mean (SD). (E) Decrease in c-Myc expression overtime after treatment with 10 μg/mL MTL-CEBPA. One-way ANOVA with Holm-Sidak multiple comparison test; n = 2–3. Data represented as mean (SD). (F) Representative western blot of c-Myc expression over time in MOLM-14 cells. (G) Fold change in CD11b MFI and (H) CD14 MFI in MOLM-14 cells 96 h following treatment with 10 μg/mL MTL-CEBPA or control (untreated). Two-way unpaired student t test; n = 2–3. Data represented as mean (SD).

Article Snippet: Anti-human CD11b antibody (Brilliant Ultra Violet 496, mouse, monoclonal, 1:1000, eBioscience, clone ICRF44) or anti-human CD14 antibody (Brilliant Violet 421, mouse, monoclonal, BioLegend, clone HCD14) was diluted in 2% FBS/PBS to the manufacturer-recommended concentration, and cells were incubated on ice in the dark with 100 μL of the solution for 30 min.

Techniques: Control, Comparison, Expressing, Western Blot